Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT7439 Alone and in Combination With Anticancer Treatments in Solid Malignancies
NCT06600789Phase 2Recruiting
- Sponsor
- Carrick Therapeutics
- Start
- Aug 2024
- Primary completion
- Mar 2027
- Modality
- Molecular Glues
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of CT7439 in Solid malignancy, sponsored by Carrick Therapeutics. Primary endpoints: Treatment Emergent Adverse Events, Treatment Emergent Laboratory Abnormalities and 4 more. Started Aug 2024; status: recruiting.
02
Drugs
CT7439
03
Conditions
Solid malignancy
Beyond the preview
Go deeper on NCT06600789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600789.